Neurological Disease News and Research RSS Feed - Neurological Disease News and Research

Computer-based cognitive remediation at home can improve cognitive symptoms in MS patients

Computer-based cognitive remediation at home can improve cognitive symptoms in MS patients

Cognitive impairment is one of the core symptoms of multiple sclerosis (MS) -- and one of its most troubling concerns for many people with the condition. Now, a new study from NYU Langone Medical Center may provide hope for symptomatic relief for some of the cognitive issues associated with the neurological disease. [More]
Neural stem cells from T cell-derived iPSCs provide neurological disease model

Neural stem cells from T cell-derived iPSCs provide neurological disease model

Researchers in Japan report that neural stem cells derived from readily available T cell-derived iPSCs provide a neurological disease model when cultured in a novel protocol developed by them. The findings are important for the treatment of Parkinson’s disease and are published in Stem Cell Reports, March 2016. [More]
NIH scientists show how neurons in the eye may use math to differentiate moving objects

NIH scientists show how neurons in the eye may use math to differentiate moving objects

Our eyes constantly send bits of information about the world around us to our brains where the information is assembled into objects we recognize. Along the way, a series of neurons in the eye uses electrical and chemical signals to relay the information. In a study of mice, National Institutes of Health scientists showed how one type of neuron may do this to distinguish moving objects. [More]
Understanding range of neurological disease linked with Zika virus is urgent priority, warn researchers

Understanding range of neurological disease linked with Zika virus is urgent priority, warn researchers

Understanding the scale and range of neurological disease associated with Zika virus infection is an urgent priority, warn researchers from the University of Liverpool's Institute of Infection and Global Health. [More]
Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Novartis today announced that the United States Food and Drug Administration approved Afinitor (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. [More]
Novartis receives FDA Breakthrough Therapy designation for PKC412 (midostaurin)

Novartis receives FDA Breakthrough Therapy designation for PKC412 (midostaurin)

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy designation to PKC412 (midostaurin). PKC412 (midostaurin) is an investigational treatment for adults with newly-diagnosed AML who are FLT3 mutation-positive, as detected by an FDA-approved test, and who are eligible to receive standard induction and consolidation chemotherapy. [More]
Pioglitazone drug may prevent recurrent stroke and heart attacks

Pioglitazone drug may prevent recurrent stroke and heart attacks

Pioglitazone, a drug used for type 2 diabetes, may prevent recurrent stroke and heart attacks in people with insulin resistance but without diabetes. [More]
Researchers reveal how brain-specific microRNA plays key role in causing abnormal brain development

Researchers reveal how brain-specific microRNA plays key role in causing abnormal brain development

Autism Spectrum Disorders (ASDs) are a group of highly inheritable behavioural disorders that pose major personal and public health concerns. Patients with ASDs have mild to severe communication difficulties, repetitive behaviour and social challenges. Such disorders significantly challenge an individual's ability to conduct daily activities and function normally in society. Currently there are very few medication options that effectively treat ASDs. [More]
Synthetic RNA and DNA could reverse protein deficiency that causes Friedreich's ataxia

Synthetic RNA and DNA could reverse protein deficiency that causes Friedreich's ataxia

Researchers at UT Southwestern Medical Center have identified synthetic RNA and DNA that reverses the protein deficiency causing Friedreich's ataxia, a neurological disease for which there is currently no cure. [More]
Researchers identify how Toxoplasma parasite crosses blood-brain barrier

Researchers identify how Toxoplasma parasite crosses blood-brain barrier

An estimated 30 percent of the world's population is chronically infected with the parasite Toxoplasma gondii. Most people live with the infection without noticeable effect, but it can be life-threatening for people with suppressed immune systems, such as people on cancer therapies or who have HIV/AIDS. [More]
Taste deficits appear to be more prevalent in MS patients

Taste deficits appear to be more prevalent in MS patients

Taste deficits appear to be more prevalent among multiple sclerosis (MS) patients than previously reported and correlate with brain lesions left by the debilitating disease, a new study from the University of Pennsylvania's Smell and Taste Center and the department of Radiology found. [More]
Clinicoradiological syndromes allow rapid recognition of EV71 neurological problems

Clinicoradiological syndromes allow rapid recognition of EV71 neurological problems

Severe enterovirus 71 neurological disease in children predominantly involves the spinal cord and brainstem and can be quickly recognised using the World Health Organisation classification of clinicoradiological syndromes, study findings suggest. [More]
Researchers identify protein that could protect against toxic degeneration of cells in ALS

Researchers identify protein that could protect against toxic degeneration of cells in ALS

J. Gavin Daigle, a PhD candidate at the LSU Health New Orleans School of Graduate Studies, is the first author of a paper whose findings reveal another piece of the Amyotrophic Lateral Sclerosis (ALS) puzzle. [More]
Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announced today that the US Food and Drug Administration has approved Cosentyx (secukinumab) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). [More]
Scientists identify unusual regulator of body weight, metabolic syndrome

Scientists identify unusual regulator of body weight, metabolic syndrome

Scientists at the Gladstone Institutes have discovered an unusual regulator of body weight and the metabolic syndrome: a molecular mechanism more commonly associated with brain cells. Lowering levels of P75 neurotrophin receptor (NTR)--a receptor involved in neuron growth and survival--protected mice fed a high-fat diet from developing obesity, diabetes, and fatty liver disease. [More]
Leading researchers reject proposed link between adeno-associated virus 2 and hepatocellular carcinoma

Leading researchers reject proposed link between adeno-associated virus 2 and hepatocellular carcinoma

The conclusion drawn from a recent study that insertion of adeno-associated virus 2 (AAV2) into human DNA causes mutations leading to the development of hepatocellular carcinoma (HCC) was resoundingly rejected by leading researchers in the fields of gene therapy and molecular genetics. [More]
Researchers link idiopathic congenital nystagmus to a defect in neurocomputation

Researchers link idiopathic congenital nystagmus to a defect in neurocomputation

Botond Roska and his group at the Friedrich Miescher Institute for Biomedical Research implicate a clearly defined neuron type and its circuit in the retina in the pathophysiology of idiopathic congenital nystagmus. [More]
FDA grants Orphan Drug Designation to Ionis Pharmaceuticals' IONIS-HTT Rx for treatment of HD patients

FDA grants Orphan Drug Designation to Ionis Pharmaceuticals' IONIS-HTT Rx for treatment of HD patients

Ionis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to IONIS-HTTRx for the treatment of patients with Huntington's disease (HD). [More]
NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine. [More]
Inorganic mercury can damage key cell processes, finds UGA study

Inorganic mercury can damage key cell processes, finds UGA study

University of Georgia research has found that inorganic mercury, which was previously thought to be a less harmful form of the toxic metal, is very damaging to key cell processes. [More]
Advertisement
Advertisement